JUNE 21st, 2005
Psivida has announced the issuance of another patent. This patent,
a Korean patent, refers to the electronic based properties of BioSilicon, the company's silicon based tissue repair scaffolds.
BioSilicon scaffolds give a directed path for tissue to attach itself to and grow.
One of the applications Psivida refers to the use of Micro-electro-mechanical
devices to assist in the implant process and for hip and knee prostheses applications. One use of MEMS devices is to measure
bone strength and strain. Hip replacement operations require significant post-operative monitoring to ensure that the replacement
procedure doesn't result in complications.
pSivida Managing Director, Gavin Rezos summarized the market
briefly, "The global market for products enhancing bone growth and fusion is growing rapidly and this trend is likely to continue
as the requirement for specialist management of a variety of orthopedic conditions increases."
The patent was assigned Korean Patent Number 488643.
JUNE 13th, 2005
Manufacturers of healthcare products, through BioElectronics Corporation
(Pink sheets: BIEL), now have access to the company's ActiPatch, a drug-free patch used to reduce swelling. BioElectronics
foresees manufactures of orthotics, braces, splints and wraps embedded the ActiPatch within their products.
The company apparently has some major contracts in the works. According
to Andrew J. Whelan, President and CEO. "We have been working diligently on this design approach for months and we have our
existing products working well with a couple of well respected companies. We expect to be announcing some major deals in the
coming months, beginning with the European market. This approach will add greatly to our goal of making our breakthrough medical
products available for a broad array of soft tissue injuries."
ActiPatch is referred to be the company as dermal patch. The dermal
patch contains a battery-powered microchip that delivers continuous pulsed therapy.
JUNE 9th, 2005
Amenni has started the process of filling the 300,000 patch order
for its first United States client as part of the company’s sales program that addresses a market that Amenni believes,
for its Sports Patch alone, could reach $500 million annually.
The Sports Patch has been aimed at the Sports Healthcare market
. The company has stated that the Amenni Sports Patch "has shown significant benefits to aid the recovery from a Sports injury"
and when "applied immediately after injury helps with quicker recovery times." The company also believes there are currently
no direct competitors.
According to Pat Lochrie, CEO of Amenni, the company has other patch
plans, "We plan to follow the Sports Patch roll-out with further products from our Healthcare, Cosmetic and Medical ranges.
The use of a Transdermal Patch delivery system promises to be very exciting."
The primary active ingredients of the Sports Patch were based on
research in Veterinary Science.
MAY 19th, 2005
BioMimetic Pharmaceuticals, a company that develops products for
musculoskeletal disorders, reported the second closing of a Series C round of financing. The funding adds $11.8 million to
the $25.7 million raised in the first closing of the Series C round. Investors included Axiom Ventures, CMEA Ventures, HSS
Ventures, InterWest Partners, Knowledge Ventures LLC, MB Venture Partners, MC Life Science Ventures, Noro-Moseley and PTV
Samuel E. Lynch, D.M.D., D.M.Sc., CEO of BioMimetic Pharmaceuticals
outlined plans for the funding, "In addition to supporting the final phases of FDA approval and the launch of our lead product
candidate, GEM 21S, the additional funds raised will help us advance our multi-product orthopedic pipeline deep into clinical
development." GEM 21S, according to the company, has been developed for the treatment of bone defects in the jaw and maxillofacial
Besides GEM 21S inventory build-up, the company indicates that the
funds will also be used to expand its staff and corporate headquarters. Since its inception in 2001, BioMimetic has raised
$51 million in equity funding.